Statin therapy and stroke prevention: What was known, what is new and what is next?

Current Opinion in Lipidology

Volumn 18, Issue 6, 2007, Pages 622-625

  Mazighi, Mikael ^a   Lavallée, Philippa C ^a   Labreuche, Julien ^a   Amarenco, Pierre ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Lipid lowering therapy; Statin; Stroke; Stroke prevention

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO;

CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; HUMAN; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZATION; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; RISK REDUCTION; SECONDARY PREVENTION; STATISTICAL SIGNIFICANCE; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANTICHOLESTEREMIC AGENTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISCHEMIC ATTACK, TRANSIENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; STROKE;

EID: 36048966568     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3282f19ede     Document Type: Review

References (19)

1. Rothwell PM, Coull AJ, Silver LE, et al. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 2005; 366:1773-1783.
2. Gongora-Rivera F, Labreuche J, Jaramilo A, et al. The prevalence of coronary atherosclerosis in patients with stroke. Stroke 2007; 38:1203-1210. Surprisingly the first autopsy evidences establishing the prevalence of coronary atherosclerosis in patients with stroke, by stroke subtype and by presence or absence of carotid atherosclerosis.
3. Dhamoon MS, Sciacca RR, Rundek T, et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 2006; 66:641-646. Population-based epidemiologic study giving event rates after a first ischemic stroke in the context of modern secondary stroke prevention.
4. Sacco RL, Benjamin EJ, Broderick JP, et al. American Heart Association Prevention Conference. IV. Prevention and rehabilitation of stroke. Risk Factors Stroke 1997; 28:1507-1517.
5. MacMahon S. Blood pressure and the prevention of stroke. J Hypertens 1996; 14 (S6):39-46.
6. Amarenco P, Lavallée P, Touboul P-J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol 2004; 3:271-278.
7. Amarenco P. The effects of statins in stroke prevention. Curr Opin Lipidol 2005; 16:614-618.
8. Amarenco P, Labreuche J, Lavallee P, et al. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 2004; 35:2902-2909.
9. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278.
10. LaRosa JC, Grundy SM, Waters DD, et al., for the Treating to New Target (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
11. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364:685-696.
12. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149-1158.
13. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361:2005-2016.
14. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al., for the SPARCL investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-555. This study is the only trial dedicated to secondary stroke prevention with statin therapy, and brings the first evidence for a positive effect of statin in this setting.
15. Amarenco P, Goldstein LB, Szarek M, et al. for the SPARCL Investigators. Effects of intense LDL-C reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke 2007; 38: in press.
16. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
17. Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. J Am Med Assoc 2005; 294:2427-2445.
18. Koren MJ, Hunninghake DB, on behalf of the ALLIANCE investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The ALLIANCE Study. J Am Coll Cardiol 2004; 44:1772-1779.
19. De Lemos JA, Blazing MA, Wiviott SD, et al., for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. J Am Med Assoc 2004; 292:1307-1316.